PMID- 36599769
OWN - NLM
STAT- MEDLINE
DCOM- 20230324
LR  - 20230329
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 23
IP  - 3
DP  - 2023 Apr
TI  - Efficacy and Safety of First-line Carboplatin-paclitaxel and 
      Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: 
      A Monocentric, Retrospective Comparison.
PG  - e151-e162
LID - S1526-8209(22)00286-5 [pii]
LID - 10.1016/j.clbc.2022.12.008 [doi]
AB  - BACKGROUND: Platinum-based chemotherapy is widely used in patients with advanced 
      triple-negative breast cancer (TNBC). However, the most effective platinum-based 
      combination in the first-line treatment setting remains unclear. MATERIALS AND 
      METHODS: We evaluated the efficacy of first-line carboplatin-paclitaxel (CP) or 
      carboplatin-gemcitabine (CG) combinations in advanced TNBC patients treated 
      between April 2007 and April 2021. CP and CG were compared in terms of 
      progression-free survival (PFS), overall survival (OS), and incidence of adverse 
      events (AEs). Multivariable Cox Models were used to adjust the efficacy of CP 
      versus CG for clinically relevant covariates. RESULTS: Of 88 consecutive advanced 
      TNBC patients receiving first-line carboplatin-based doublets, 56 (63.6%) 
      received CP and 32 (36.4%) CG. After adjusting for clinically relevant variables, 
      patients receiving CG had significantly better PFS when compared to CP-treated 
      patients (HR: 0.49 (95% CI, 0.27-0.87), P value 0.014). Of note, CG was 
      associated with better PFS only among patients previously treated with taxanes in 
      the (neo)adjuvant setting (HR: 0.39; 95% CI, 0.21-0.75), but not in patients not 
      exposed to taxanes (HR: 1.20; 95% CI, 0.37-3.88). CG was also independently 
      associated with better OS when compared to CP (HR: 0.31 (95% CI: 0.15-0.64), P 
      value 0.002). Overall, grade 3-4 AEs were more common in patients treated with CG 
      than in patients treated with CP (68.8% vs. 21.4%, P value .009). CONCLUSION: CG 
      and CP are effective and well tolerated first-line platinum doublets in advanced 
      TNBC patients. CG could be more effective than CP in patients previous exposed to 
      taxanes despite worse toxicity profile.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Lobefaro, Riccardo
AU  - Lobefaro R
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Mariani, Luigi
AU  - Mariani L
AD  - Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto 
      Nazionale dei Tumori, Milan, Italy.
FAU - Peverelli, Giorgia
AU  - Peverelli G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Ligorio, Francesca
AU  - Ligorio F
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Fuca, Giovanni
AU  - Fuca G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Rametta, Alessandro
AU  - Rametta A
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Zattarin, Emma
AU  - Zattarin E
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Leporati, Rita
AU  - Leporati R
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Presti, Daniele
AU  - Presti D
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Cantarelli, Beatrice
AU  - Cantarelli B
AD  - IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.
FAU - Depretto, Catherine
AU  - Depretto C
AD  - Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
      Italy.
FAU - Vingiani, Andrea
AU  - Vingiani A
AD  - Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
      Italy; Department of Oncology and Haematology, University of Milan, Milan, Italy.
FAU - Manoukian, Siranoush
AU  - Manoukian S
AD  - Unit of Medical Genetics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
      Italy.
FAU - Scaperrotta, Gianfranco
AU  - Scaperrotta G
AD  - Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
      Italy.
FAU - Bianchi, Giulia V
AU  - Bianchi GV
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Capri, Giuseppe
AU  - Capri G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Pruneri, Giancarlo
AU  - Pruneri G
AD  - Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
      Italy; Department of Oncology and Haematology, University of Milan, Milan, Italy.
FAU - de Braud, Filippo
AU  - de Braud F
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy; Department of Oncology and Haematology, University of Milan, Milan, 
      Italy.
FAU - Vernieri, Claudio
AU  - Vernieri C
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy; IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy. 
      Electronic address: claudio.vernieri@istitutotumori.mi.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221217
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - BG3F62OND5 (Carboplatin)
RN  - 0 (Gemcitabine)
RN  - 0W860991D6 (Deoxycytidine)
RN  - P88XT4IS4D (Paclitaxel)
RN  - 0 (Taxoids)
SB  - IM
CIN - Clin Breast Cancer. 2023 Apr;23(3):e55. PMID: 36775765
MH  - Humans
MH  - Carboplatin
MH  - *Gemcitabine
MH  - *Triple Negative Breast Neoplasms/drug therapy
MH  - Retrospective Studies
MH  - Deoxycytidine/adverse effects
MH  - Paclitaxel
MH  - Taxoids/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Advanced triple-negative breast cancer
OT  - Carboplatin- gemcitabine
OT  - Carboplatin-paclitaxel
OT  - Overall Survival
OT  - Progression Free Survival
EDAT- 2023/01/05 06:00
MHDA- 2023/03/25 06:00
CRDT- 2023/01/04 21:55
PHST- 2022/07/22 00:00 [received]
PHST- 2022/11/19 00:00 [revised]
PHST- 2022/12/14 00:00 [accepted]
PHST- 2023/01/05 06:00 [pubmed]
PHST- 2023/03/25 06:00 [medline]
PHST- 2023/01/04 21:55 [entrez]
AID - S1526-8209(22)00286-5 [pii]
AID - 10.1016/j.clbc.2022.12.008 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2023 Apr;23(3):e151-e162. doi: 10.1016/j.clbc.2022.12.008. 
      Epub 2022 Dec 17.